{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:44:26Z","timestamp":1787589866576,"version":"build-2736575974"},"reference-count":59,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.1080\/14740338.2025.2596231","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T13:08:16Z","timestamp":1764335296000},"page":"813-822","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["CYP450 activity, drug interactions, and genetic polymorphisms: clinical relevance for the new selective cardiac myosin inhibitors"],"prefix":"10.1080","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0010-9797","authenticated-orcid":false,"given":"Milind Y.","family":"Desai","sequence":"first","affiliation":[{"name":"Cleveland Clinic","place":["Cleveland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Michaud","sequence":"additional","affiliation":[{"name":"GalenusRx Inc","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Thacker","sequence":"additional","affiliation":[{"name":"GalenusRx Inc","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Arwood","sequence":"additional","affiliation":[{"name":"GalenusRx Inc","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Dow","sequence":"additional","affiliation":[{"name":"GalenusRx Inc","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Martinez","sequence":"additional","affiliation":[{"name":"Atlantic Health System","place":["Morristown, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Michels","sequence":"additional","affiliation":[{"name":"Erasmus University Medical Center","place":["Rotterdam, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali T.","family":"Owens","sequence":"additional","affiliation":[{"name":"University of Pennsylvania","place":["Philadelphia, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Turgeon","sequence":"additional","affiliation":[{"name":"GalenusRx Inc","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"issue":"4","key":"e_1_3_6_3_1","first-page":"3","article-title":"Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients","volume":"30","author":"Braunwald E","year":"1964","unstructured":"Braunwald E, Lambrew CT, Rockoff SD, et al. Idiopathic hypertrophic subaortic stenosis. I. A description of the disease based upon an analysis of 64 patients. Circulation. 1964;30(SUPPL 4):3\u2013119.","journal-title":"Circulation"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad194"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001250"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.776815"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c01290"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3005"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1332"},{"key":"e_1_3_6_10_1","unstructured":"Center for Drug Evaluation and Research. Integrated clinical pharmacology review NDA-214998 (mavacamten)."},{"key":"#cr-split#-e_1_3_6_11_1.1","unstructured":"Bristol-Myers Squibb Canada. Camzyos(TM). 2024 [updated 2024 Feb 14"},{"key":"#cr-split#-e_1_3_6_11_1.2","unstructured":"cited 2025 May 7]. Available from: https:\/\/pdf.hres.ca\/dpd_pm\/00074626.PDF"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2018.1495856"},{"key":"#cr-split#-e_1_3_6_13_1.1","unstructured":"U.S. Food and Drug Administration. Cazmyos - highlights of prescribing information (drug product label): U.S. Food and Drug Administration. 2023 [updated 2023 June"},{"key":"#cr-split#-e_1_3_6_13_1.2","unstructured":"cited 2025 May 7]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/214998s001lbl.pdf"},{"key":"#cr-split#-e_1_3_6_14_1.1","unstructured":"European Medicines Agency. Assessment report: camzyos 2023 [updated 2023 Apr 26"},{"key":"#cr-split#-e_1_3_6_14_1.2","unstructured":"cited 2025 May 7]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/camzyos-epar-public-assessment-report_en.pdf"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1496"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70006"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2022.04.008"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1227470"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498254.2024.2389407"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(25)01912-6"},{"key":"e_1_3_6_21_1","first-page":"85","article-title":"Drug-drug interactions study to evaluate the effect of strong CYP3A4 inhibition and induction on the pharmacokinetics of aficamten, and the effect of aficamten on P-glycoprotein in healthy participants","author":"Xu D","year":"2024","unstructured":"Xu D, Lutz J, Divanji P, et al. Drug-drug interactions study to evaluate the effect of strong CYP3A4 inhibition and induction on the pharmacokinetics of aficamten, and the effect of aficamten on P-glycoprotein in healthy participants. Clin Pharmacol Ther. 2024:85.","journal-title":"Clin Pharmacol Ther"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2024.02.001"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.012441"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389200023337054"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-020-02936-7"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2022.12.012"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12090846"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/jbt.20180"},{"key":"e_1_3_6_29_1","unstructured":"Kalow W. Pharmacogenetics: heredity and the response to drugs. 1962."},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(78)90363-6"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)91430-1"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-021-00280-7"},{"issue":"12","key":"e_1_3_6_33_1","first-page":"13328","article-title":"Illustrative and historic cases of phenoconversion","volume":"13","author":"Michaud V","year":"2021","unstructured":"Michaud V, Dow P, Turgeon J. Illustrative and historic cases of phenoconversion. Am J Transl Res. 2021;13(12):13328\u201313335.","journal-title":"Am J Transl Res"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12441"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9092890"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2025.2451440"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312791"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2016.09.015"},{"key":"e_1_3_6_39_1","unstructured":"Grangeon A Arwood M Thacker D et al. Reveals that CYP2C9 is the most abundant isoform in the liver. Submitted manuscript."},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2019.05.006"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270002239710"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.113.051722"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008571-199810000-00001"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm8010008"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.GIM.0000153664.65759.CF"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.09.143"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1266\/ggs.86.109"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes11111295"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1006\/abbi.1996.0291"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.tpj.6500285"},{"key":"e_1_3_6_51_1","unstructured":"Pharmacogene Variation Consortium. Structural variation CYP2D6. 2019 [2025 Apr 15]. Available from: https:\/\/www.pharmvar.org\/gene-support\/Variation_CYP2D6.pdf"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2016.80"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10112686"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.18636"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2003.29"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.2174\/187231210791292735"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41397-019-0144-7"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8040094"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2025.2596231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:19:25Z","timestamp":1777882765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2025.2596231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,4]]}},"alternative-id":["10.1080\/14740338.2025.2596231"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2025.2596231","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-05-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}